Mauro Biffoni
Overview
Explore the profile of Mauro Biffoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
5414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tozzi M, Fiore A, Travaglione S, Marcon F, Rainaldi G, Germinario E, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):29.
PMID: 39876002
Background: Bacterial toxins are emerging as promising hallmarks of colorectal cancer (CRC) pathogenesis. In particular, Cytotoxic Necrotizing Factor 1 (CNF1) from E. coli deserves special consideration due to the significantly...
2.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al.
Nat Immunol
. 2024 Sep;
25(11):2166.
PMID: 39289560
No abstract available.
3.
Vitale S, Calapa F, Colonna F, Luongo F, Biffoni M, De Maria R, et al.
Adv Sci (Weinh)
. 2024 Jul;
11(32):e2405084.
PMID: 38962943
The process of drug discovery and pre-clinical testing is currently inefficient, expensive, and time-consuming. Most importantly, the success rate is unsatisfactory, as only a small percentage of tested drugs are...
4.
Castellani G, Buccarelli M, DAlessandris Q, Ilari R, Cappannini A, Pedini F, et al.
Cancer Cell Int
. 2024 Feb;
24(1):72.
PMID: 38347567
Background: Glioblastoma (GBM) is the most lethal primary brain tumor in adult, characterized by highly aggressive and infiltrative growth. The current therapeutic management of GBM includes surgical resection followed by...
5.
Arasi M, De Luca G, Chronopoulou L, Pedini F, Petrucci E, Flego M, et al.
Mol Ther
. 2023 Nov;
32(1):152-167.
PMID: 37990493
Metastatic melanoma poses significant challenges as a highly lethal disease. Despite the success of molecular targeting using BRAF inhibitors (BRAFis) and immunotherapy, the emergence of early recurrence remains an issue...
6.
Romagnoli G, DAlessandris Q, Capone I, Tavilla A, Canini I, Lapenta C, et al.
Immunology
. 2023 Oct;
171(2):198-211.
PMID: 37884280
Glioblastoma, isocitrate dehydrogenase-wildtype (GB), is the most common and aggressive primary brain malignancy with poor outcome. Immune checkpoint inhibitors (ICIs) have been tested in GB and, despite disappointing results, the...
7.
Lo Cicero S, Castelli G, Blacona G, Bruno S, Sette G, Pigliucci R, et al.
Respir Res
. 2023 Sep;
24(1):228.
PMID: 37742000
No abstract available.
8.
Lo Cicero S, Castelli G, Blacona G, Bruno S, Sette G, Pigliucci R, et al.
Respir Res
. 2023 Sep;
24(1):217.
PMID: 37674160
Cystic fibrosis (CF) is caused by defects of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR-modulating drugs may overcome specific defects, such as the case of Trikafta, which is...
9.
Coppola V, Marino I, Warnken U, Falchi M, Pasquini L, Biffoni M, et al.
Autophagy
. 2023 Jul;
19(10):2733-2751.
PMID: 37418591
Apoptosis is a tightly controlled cell death program executed by proteases, the so-called caspases. It plays an important role in tissue homeostasis and is often dysregulated in cancer. Here, we...
10.
Petroulakis N, Mattsson M, Chatziadam P, Simko M, Gavrielides A, Yiorkas A, et al.
Int J Environ Res Public Health
. 2023 Jun;
20(12).
PMID: 37372672
The evolution of emerging technologies that use Radio Frequency Electromagnetic Field (RF-EMF) has increased the interest of the scientific community and society regarding the possible adverse effects on human health...